ANDAORALTABLET
Approved
Mar 2017
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
1
Mechanism of Action
Nucleoside Reverse Transcriptase Inhibitors
Pharmacologic Class:
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Clinical Trials (1)
A Study Comparing Safety Of Abacavir And Lamivudine Administered Once-Daily As A Single Tablet Versus The Same Drugs Administered Twice-Daily As Separate Tablets (ALOHA Study)
Started Jul 2004
900 enrolled
HIV Infection